These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 22658385)

  • 21. Treatment of metastatic renal cell cancer with sunitinib during chronic hemodialysis.
    Zastrow S; Froehner M; Platzek I; Novotny V; Wirth MP
    Urology; 2009 Apr; 73(4):868-70. PubMed ID: 19167044
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical activity of sorafenib and sunitinib in renal cell carcinoma refractory to previous vascular endothelial growth factor-targeted therapy: two case reports.
    Shaheen PE; Rini BI; Bukowski RM
    Clin Genitourin Cancer; 2006 Jun; 5(1):78-81. PubMed ID: 16859583
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sunitinib in renal-cell carcinoma: expanded indications.
    Choueiri TK; Bellmunt J
    Lancet Oncol; 2009 Aug; 10(8):740. PubMed ID: 19615941
    [No Abstract]   [Full Text] [Related]  

  • 24. Complete cerebral response with sunitinib for metastatic renal cell carcinoma.
    Medioni J; Cojocarasu O; Belcaceres JL; Halimi P; Oudard S
    Ann Oncol; 2007 Jul; 18(7):1282-3. PubMed ID: 17675397
    [No Abstract]   [Full Text] [Related]  

  • 25. 'Sunitinib withdrawal phenomenon' or spontaneous regression in renal cell cancer.
    Rothermundt CA; Omlin A; Gillessen S
    Ann Oncol; 2009 Jun; 20(6):1144-6. PubMed ID: 19465428
    [No Abstract]   [Full Text] [Related]  

  • 26. Rapid involution of choroidal metastasis secondary to renal cell carcinoma with oral sunitinib.
    Chin EK; Almeida DR; Sacher BA; Boldt HC
    JAMA Ophthalmol; 2015 Jan; 133(1):109-10. PubMed ID: 25321845
    [No Abstract]   [Full Text] [Related]  

  • 27. [Sunitinib versus interferon-alpha in metastatic renal-cell carcinoma].
    Irani J
    Prog Urol; 2007 Sep; 17(5):996. PubMed ID: 17969805
    [No Abstract]   [Full Text] [Related]  

  • 28. [Treatment with sunitinib and hypothyroidism--a case report and overview of literature].
    Kreze A; Stáhalová V; Zadrazilová A; Koskuba J; Kosák M
    Klin Onkol; 2009; 22(4):176-8. PubMed ID: 19731880
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Advanced sarcomatoid renal cell carcinoma effectively treated with sunitinib: report of a case].
    Tsuchiyama K; Ito H; Ishida H; Itoh H; Yokoyama O
    Hinyokika Kiyo; 2011 Nov; 57(11):615-8. PubMed ID: 22166824
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sunitinib, pazopanib or sorafenib for the treatment of patients with late relapsing metastatic renal cell carcinoma.
    Santoni M; Conti A; Porta C; Procopio G; Sternberg CN; Basso U; De Giorgi U; Bracarda S; Rizzo M; Ortega C; Massari F; Iacovelli R; Derosa L; Masini C; Milella M; Di Lorenzo G; Atzori F; Pagano M; Buti S; De Vivo R; Mosca A; Rossi M; Paglino C; Verzoni E; Cerbone L; Muzzonigro G; Falconi M; Montironi R; Burattini L; Santini D; Cascinu S
    J Urol; 2015 Jan; 193(1):41-7. PubMed ID: 25046616
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Reversible myocardial dysfunction in a young woman with metastatic renal cell carcinoma treated with sunitinib.
    Szmit S; Nurzyński P; Szaluś N; Opolski G; Szczylik C
    Acta Oncol; 2009; 48(6):921-5. PubMed ID: 19191048
    [No Abstract]   [Full Text] [Related]  

  • 32. Hypertension as a predictive factor of Sunitinib activity.
    Rixe O; Billemont B; Izzedine H
    Ann Oncol; 2007 Jun; 18(6):1117. PubMed ID: 17586751
    [No Abstract]   [Full Text] [Related]  

  • 33. Optimizing the use of sunitinib in metastatic renal cell carcinoma: an update from clinical practice.
    Schmidinger M; Arnold D; Szczylik C; Wagstaff J; Ravaud A
    Cancer Invest; 2010 Oct; 28(8):856-64. PubMed ID: 20504222
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sunitinib treatment of metastatic renal cell carcinoma in von Hippel-Lindau disease.
    Tsimafeyeu I
    J Cancer Res Ther; 2015; 11(4):920-2. PubMed ID: 26881543
    [TBL] [Abstract][Full Text] [Related]  

  • 35. New challenges in kidney cancer therapy: sunitinib.
    Izzedine H; Billemont B; Thibault F; Rixe O
    Ann Oncol; 2007 Jul; 18 Suppl 9():ix83-6. PubMed ID: 17631600
    [No Abstract]   [Full Text] [Related]  

  • 36. Regression of brain metastases of renal cell carcinoma with antiangiogenic therapy.
    Thibault F; Billemont B; Rixe O
    J Neurooncol; 2008 Jan; 86(2):243-4. PubMed ID: 17634858
    [No Abstract]   [Full Text] [Related]  

  • 37. Word of wisdom. Re: clinical outcomes for patients with metastatic renal cell carcinoma treated with alternative sunitinib schedules.
    Zigeuner R
    Eur Urol; 2014 Oct; 66(4):785. PubMed ID: 25218072
    [No Abstract]   [Full Text] [Related]  

  • 38. Sunitinib (SUTENT) for the treatment of metastatic renal cell carcinoma.
    Hutson TE
    Expert Rev Anticancer Ther; 2008 Nov; 8(11):1723-31. PubMed ID: 18928373
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Response to sunitinib in an adult patient with rhabdoid renal cell carcinoma.
    De Vincenzo F; Zucali PA; Ceresoli GL; Colombo P; Simonelli M; Lorenzi E; Perrino M; Gianoncelli L; De Sanctis R; Graziotti P; Santoro A
    J Clin Oncol; 2011 Jun; 29(18):e529-31. PubMed ID: 21483010
    [No Abstract]   [Full Text] [Related]  

  • 40. Efficacy of Rechallenge of Metastatic Renal Cell Carcinoma Patient With Sunitinib After Prior Resistance to Axitinib: Case Report and Review of the Literature.
    Daste A; Gross-Goupil M; Quivy A; François L; Bernhard JC; Ravaud A
    Clin Genitourin Cancer; 2016 Oct; 14(5):e525-e527. PubMed ID: 27185091
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.